Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $18.30 Consensus Target Price from Brokerages
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eleven brokerages that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating […]
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eleven brokerages that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating […]
